Fujian-based pharmaceutical/biotech company; specific pipeline and products not fully confirmed from available knowledge.
Fujian-based pharmaceutical/biotech company; specific pipeline and products not fully confirmed from available knowledge.
Moat: none
Headquarters: Fujian, China · Employees: 715
Size Fujian Cosunter Pharmaceutical (300436.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.02B, the 1155th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥67.56 on 18 Nov 2026.
Performance Over six months the shares fell 44.8%, against -1.3% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue fell 0.4% over the last twelve months (peer median +11.1%); the operating margin is -47.0% (peer median 22.2%).
Valuation It trades at 30.9× enterprise value to sales against a peer median of 4.8× (most expensive of 20).
Capital Return on invested capital runs 28.2 points below its cost of capital (14.1% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥429M | CN¥413M | CN¥438M | CN¥414M | CN¥382M |
| Revenue growth | — | -6% | +6% | +8% | — |
| Gross profit | CN¥298M | CN¥214M | CN¥229M | CN¥199M | CN¥197M |
| EBITDA | n/a | -CN¥35.8M | -CN¥46.2M | -CN¥135M | -CN¥173M |
| Net income | -CN¥210M | -CN¥218M | -CN¥156M | -CN¥349M | -CN¥127M |
| Free cash flow | -CN¥138M | -CN¥94.6M | -CN¥28.6M | -CN¥376M | -CN¥315M |
| Capital expenditure | CN¥81.4M | CN¥59.5M | CN¥67.0M | CN¥201M | CN¥196M |
| Total debt | CN¥485M | CN¥728M | CN¥697M | CN¥696M | CN¥313M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Fujian Cosunter Pharmaceutical 300436.SZ | $2.02B | -45% | 0% | -47% | 30.9× | n/a |
| Gilead Sciences GILD | $210B | +30% | +7% | 38% | 7.3× | -2.4% |
| Sbp 1177.HK | $12.2B | +5% | +15% | 30% | 2.6× | -5.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300436.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.7% | +2.7% | lowest of 21 |
| 6-month return | -44.8% | -1.3% | lowest of 21 |
| Distance from 52-week high | -54.7% | -28.2% | lowest of 21 |
| Revenue growth (TTM) | -0.4% | +11.1% | 4th lowest of 20 |
| Operating margin | -47.0% | 22.2% | lowest of 20 |
| EV / Sales | 30.9× | 4.8× | most expensive of 20 |
| ROIC minus cost of capital | -28.2 pp | +1.6 pp | lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.02B | -45% | 0% | -47% | 30.9× | n/a | n/a |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.03B | +19% | -1% | 14% | 2.4× | 1.7% | +15.7% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.03B | -3% | +9% | 14% | 3.2× | 5.1% | +6.4% |
| Hanall Biopharma 009420.KS | South Korea | $2.01B | +12% | +5% | 3% | 16.6× | n/a | n/a |
| InnoCare Pharma 9969.HK | Hong Kong | $2.01B | -10% | +146% | 35% | 2.8× | -2.0% | +341.1% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.04B | +9% | +5% | 22% | 3.3× | -4.7% | +10.6% |
| Eris Lifesciences ERIS.NS | India | $1.98B | 0% | +11% | 26% | 6.2× | 26.3% | +20.9% |
| Haw Par H02.SI | Singapore | $2.08B | -25% | -13% | 30% | 8.4× | 3.2% | +15.7% |
| Biohaven BHVN | United States | $1.95B | +46% | n/a | n/a | n/a | n/a | n/a |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.95B | -14% | +11% | 6% | 11.8× | n/a | n/a |
| Harmony Biosciences HRMY | United States | $1.94B | +6% | +20% | 22% | 1.4× | -10.5% | +40.3% |
| PharmaResearch 214450.KS | South Korea | $2.10B | -24% | +29% | 37% | 4.0× | -11.0% | +37.6% |
| Jinyu Bio-Technology 600201.SS | China | $1.93B | -21% | +22% | 10% | 7.3× | 23.4% | -2.5% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 2.0× | n/a | n/a |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 1.5× | 1.2% | +14.1% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 10.1× | n/a | n/a |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 6.3× | 20.1% | +6.2% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 5.5× | 11.2% | +2.4% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 4.8× | 8.0% | +9.3% |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 3.4× | -1.2% | +16.7% |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 8.6× | n/a | n/a |